

## Effectiveness of intrapartum fetal surveillance to improve maternal and neonatal outcomes

Al Wattar, Bassel H; Honess, Emma; Bunnewell, Sarah; Welton, Nicky J; Quenby, Siobhan; Khan, Khalid S; Zamora, Javier; Thangaratinam, Shakila

DOI:  
[10.1503/cmaj.202538](https://doi.org/10.1503/cmaj.202538)

License:  
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*  
Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*  
Al Wattar, BH, Honess, E, Bunnewell, S, Welton, NJ, Quenby, S, Khan, KS, Zamora, J & Thangaratinam, S 2021, 'Effectiveness of intrapartum fetal surveillance to improve maternal and neonatal outcomes: a systematic review and network meta-analysis', *Canadian Medical Association Journal*, vol. 193, no. 14, pp. E468-E477. <https://doi.org/10.1503/cmaj.202538>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Effectiveness of intrapartum fetal surveillance to improve maternal and neonatal outcomes: a systematic review and network meta-analysis

Bassel H. Al Wattar PhD, Emma Honess MBChB, Sarah Bunnewell MBChB, Nicky J. Welton PhD, Siobhan Quenby PhD, Khalid S. Khan MSc, Javier Zamora PhD, Shakila Thangaratinam PhD

■ Cite as: *CMAJ* 2021 April 6;193:E468-77. doi: 10.1503/cmaj.202538

## ABSTRACT

**BACKGROUND:** Cesarean delivery is the most common surgical procedure worldwide. Intrapartum fetal surveillance is routinely offered to improve neonatal outcomes, but the effects of different methods on the risk of emergency cesarean deliveries remains uncertain. We conducted a systematic review and network meta-analysis to evaluate the effectiveness of different types of fetal surveillance.

**METHODS:** We searched MEDLINE, Embase and CENTRAL until June 1, 2020, for randomized trials evaluating any intrapartum fetal surveillance method. We performed a network meta-analysis within a frequentist framework. We assessed the quality and network inconsistency of trials. We reported primarily

on intrapartum emergency cesarean deliveries and other secondary maternal and neonatal outcomes using risk ratios (RRs) and 95% confidence intervals (CIs).

**RESULTS:** We included 33 trials (118 863 patients) evaluating intermittent auscultation with Pinard stethoscope/hand-held Doppler (IA), cardiotocography (CTG), computerized cardiotocography (cCTG), CTG with fetal scalp lactate (CTG-lactate), CTG with fetal scalp pH analysis (CTG-FBS), CTG with fetal pulse oximetry (FPO-CTG), CTG with fetal heart electrocardiogram (CTG-STAN) and their combinations. Intermittent auscultation reduced the risk of emergency cesarean deliveries compared with other types of surveillance (IA v. CTG: RR 0.83, 95% CI 0.72–0.97; IA v.

CTG-FBS: RR 0.71, 95% CI 0.63–0.80; IA v. CTG-lactate: RR 0.77, 95% CI 0.64–0.92; IA v. FPO-CTG: RR 0.75, 95% CI 0.65–0.87; IA v. FPO-CTG-FBS: RR 0.81, 95% CI 0.67–0.99; cCTG-FBS v. IA: RR 1.21, 95% CI 1.04–1.42), except STAN-CTG-FBS (RR 1.17, 95% CI 0.98–1.40). There was a similar reduction observed for emergency cesarean deliveries for fetal distress. None of the evaluated methods was associated with a reduced risk of neonatal acidemia, neonatal unit admissions, Apgar scores or perinatal death.

**INTERPRETATION:** Compared with other types of fetal surveillance, intermittent auscultation seems to reduce emergency cesarean deliveries in labour without increasing adverse neonatal and maternal outcomes.

Cesarean delivery is the most common surgical procedure worldwide, performed to expedite delivery and avoid neonatal complications. Fetal surveillance is routinely offered to patients in labour to reduce the risk of adverse neonatal outcomes, as well as the risk of unnecessary emergency cesarean deliveries and other maternal interventions. Fetal surveillance aims to detect intrapartum hypoxia from acute or subacute adverse events in labour requiring medical intervention and to reduce the risk of serious complications such as neonatal cerebral palsy, hypoxic-ischemic encephalopathy or stillbirth.

Monitoring the fetal heart rate to detect intrapartum hypoxia using simple surveillance techniques, such as the Pinard

stethoscope, has been practised for decades.<sup>1</sup> Over the last 50 years, several newer surveillance methods have been evaluated, with varied uptake in practice.<sup>2</sup> Cardiotocography (CTG) remains the most common surveillance method used in high-risk pregnancies.<sup>3</sup> However, given its limited accuracy, many researchers have evaluated its use in combination with other surveillance methods, such as fetal heart electrocardiogram (STAN), fetal scalp pH analysis (FBS) or fetal pulse oximetry (FPO), and with computer-aided decision models (cCTG) to improve its diagnostic value.<sup>4–6</sup> Despite extensive investment in clinical research, the overall effectiveness of such methods in improving maternal and neonatal outcomes remains debatable as stillbirth rates have plateaued worldwide, while cesarean delivery rates continue to rise.<sup>7,8</sup>

Existing meta-analyses evaluating different intrapartum fetal surveillance methods remain limited to head-to-head comparisons of monitoring techniques, without a comprehensive assessment of their effectiveness in improving maternal and neonatal pregnancy outcomes.<sup>4,9-13</sup> We conducted a systematic review of randomized trials and a network meta-analysis to evaluate the effectiveness of all available fetal surveillance methods in improving maternal and neonatal outcomes.

## Methods

### Search strategy

We conducted our systematic review according to a prospectively registered protocol (CRD42018118082) and reported the findings as per established guidelines.<sup>14</sup> We searched MEDLINE, Embase and Cochrane CENTRAL from database inception to June 1, 2020, for randomized trials evaluating any fetal surveillance method in labour. We developed our search strategy by consulting relevant Medical Subject Headings (MeSH) and combining key search words using Boolean operators within the NICE Healthcare Databases Advanced Search platform (hdas.nice.org.uk) (Appendix 1, available at [www.cmaj.ca/lookup/doi/10.1503/cmaj.202538/tab-related-content](http://www.cmaj.ca/lookup/doi/10.1503/cmaj.202538/tab-related-content)). We also conducted supplementary searches in Google Scholar and Scopus to identify any missing evidence. No search filters or language limitations were employed; articles in non-English languages were obtained and translated if deemed relevant. We manually screened the bibliographies of potentially relevant articles and published systematic reviews on the topic to identify any additional relevant trials. We contacted the authors of included trials seeking further information as necessary. We did not include any unpublished data in the analysis. We consulted the James Lind Library and previous Cochrane reviews to identify the primary outcome and other outcomes of interest to stakeholders. We did not involve patients in the design of our research study.

### Selection of studies and outcome reporting

Two reviewers (E.M. and S.B.) independently selected and performed data extraction, which was further checked by a third reviewer (B.H.A.). Inconsistencies and disagreements were resolved by discussion and consensus with a fourth reviewer (S.T.). We included all randomized controlled trials that evaluated the effectiveness of existing fetal surveillance methods in labour. We included studies with multiple comparison arms, those evaluating a combination of surveillance types (e.g., fetal electrocardiogram and cardiotocography) and studies involving both high- and low-risk pregnancies. We combined instruments used for the same surveillance type under the same comparison arm (e.g., Pinard stethoscope and hand-held Doppler combined as intermittent auscultation). We excluded studies that included only preterm pregnancies and those comparing different instruments for the same surveillance type (e.g., Pinard stethoscope v. hand-held Doppler for intermittent auscultation). We also excluded studies that did not report on any of the outcomes we set a priori in our protocol (e.g., studies reporting only on the number of fetal blood sampling attempts).

Our main outcome was the incidence of emergency cesarean deliveries in labour. We also reported on other maternal outcomes such as emergency cesarean delivery in labour specifically for suspected fetal distress, instrumental deliveries and instrumental deliveries specifically for suspected fetal distress. Neonatal outcomes included neonatal acidemia (diagnosed using umbilical cord blood gases, as defined by the study authors), admissions to the neonatal intensive care unit, neonatal Apgar scores < 7 at the 5th minute and perinatal death (i.e., any fetal death beyond 24 weeks' gestation, plus any neonatal death within the first week of life). We extracted data on the country of the study, the publication journal, trial settings, population characteristics, the evaluated fetal surveillance types, the criteria used to interpret the surveillance findings, the action algorithm used in the trial setting for acting on worrying fetal signs and the definition of fetal acidemia used by the trial investigators.

### Quality assessment

Two reviewers (E.H. and S.B.) independently assessed the quality of included studies using the Cochrane risk of bias assessment tool.<sup>15</sup> Each study was assessed for the quality of randomization and sequence generation, assignment concealment, outcome assessment, completeness of outcome data and selective outcome reporting. Blinding was deemed non-feasible because of the nature of the evaluated interventions and was excluded from the quality assessment. Efforts to standardize the management of patients with suspected fetal distress were taken into account when evaluating detection and outcome assessment bias. Similarly, trials that employed a quality assurance process to ensure adequate diagnosis of fetal compromise against their study protocol were deemed to have less risk of outcome assessment bias compared with those that did not employ any quality measures or report on protocol violations.

### Statistical analysis

We performed a network meta-analysis within a frequentist framework. We fit multivariate meta-analysis models with random effects using the network package in Stata,<sup>16,17</sup> exploiting the direct and indirect randomized evidence to determine the relative effects and ranking. We reported the effects of the interventions using risk ratios (RRs) with 95% confidence intervals (CIs). For the primary analysis on all emergency cesarean deliveries, we only included fetal surveillance types that were evaluated in more than 1 randomized trial, decided a priori to minimize the risk of inconsistency in the network. We also conducted a sensitivity analysis with all eligible trials reporting on the primary outcome, including those evaluated in only 1 trial. We calculated the mean rank and the surface under the cumulative ranking curve (SUCRA) for each intervention for all reported outcomes. Surveillance methods with a SUCRA value close to 100% had the highest cumulative rank (i.e., lowest likelihood) of achieving the adverse maternal or neonatal outcome.<sup>18,19</sup>

We used the design-by-treatment interaction model to check the assumption of consistency in the entire network, assuming a

common estimate for the heterogeneity variance across the different comparisons in the network.<sup>20</sup> We investigated and detected inconsistency by comparing the direct and indirect evidence within the network using the node-splitting approach,<sup>21</sup> assuming a common heterogeneity estimate within each loop (i.e., when numerous trials compare a minimum of 3 treatments to one another).<sup>22</sup> We also investigated potential sources of inconsistency within relevant trials. In cases where inconsistency was detected, we conducted a network meta-regression compared with reference treatment (cardiotocography with fetal scalp blood pH sampling), testing for 2 potential effect modifiers, gestational age (preterm v. term) and pregnancy risk status (high risk v. low risk).<sup>23</sup> All analyses were conducted using Stata statistical software, release 14 (StataCorp).<sup>16,19,24</sup>

## Results

Of 351 potentially relevant citations, we included 33 randomized trials ( $n = 120\ 151$  patients) in our systematic review (Figure 1, Table 1). Most included trials were from high-income countries (United States,  $n = 6$ ;<sup>26,27,32–34,38</sup> United Kingdom,  $n = 5$ ;<sup>28,37,40,44,54</sup> Australia,  $n = 4$ ;<sup>30,31,47,57</sup> Sweden,  $n = 4$ );<sup>25,35,55,56</sup> except for 2 studies (Tanzania and India).<sup>41,42</sup> The median sample size was 894 patients (range 100–47 062). Fifteen trials (45%)<sup>25–27,31,32,36,39,41,43–46,49,51,53</sup> included patients at 36 weeks' gestation or more, and the remaining included patients at 26–42 weeks' gestation.<sup>28–30,33–35,38,40,50,52,54,56</sup> Two-thirds of trials (73%) included patients with high-risk pregnancies,<sup>25–34,36,38,39,41,44,47,48,50,51,53,54</sup> 3 (9%) included patients with low-risk pregnancies<sup>35,37,57</sup> and 4 (12%) included pregnancies of any risk.<sup>40,42,43,52</sup> Three studies did not report on pregnancy

risks.<sup>45,46,49</sup> The inclusion and exclusion criteria of each trial are summarized in Appendix 1, Supplementary Table 1.

Overall, we evaluated 10 fetal surveillance types, including intermittent auscultation (IA), cardiotocography (CTG) alone or in combination with computer-aided cardiotocography (cCTG), fetal scalp blood lactate sampling (CTG-lactate), fetal scalp blood pH sampling (CTG-FBS), fetal pulse oximetry (FPO-CTG), fetal heart electrocardiogram (STAN-CTG) and other combinations (STAN-CTG-FBS, FPO-CTG-FBS, cCTG-FBS).


All trials conducted head-to-head comparisons of 2 fetal surveillance methods with the exception of 1 trial that used a 3-arm design.<sup>34</sup> Two methods, cCTG and STAN-CTG, were evaluated in only a single trial.<sup>26,36</sup> These methods were therefore excluded from the primary analysis and were investigated in sensitivity analyses. Twenty-eight trials reported on all emergency cesarean deliveries in labour and 23 reported on cesarean deliveries for suspected fetal distress. Appendix 1, Supplementary Table 3 summarizes the number of trials and participants contributing to each reported outcome per surveillance method. Appendix 1, Supplementary Table 4 summarizes the criteria that each trial used to interpret the findings of the fetal surveillance methods that it compared, as well as each trial's management algorithms and definitions of neonatal acidemia.

### Quality of the included studies

The overall quality of included trials was moderate (Appendix 1, Supplementary Figure 1 and Supplementary Table 7). Trials that were conducted before the year 2000 showed high risk of bias in most of the evaluated domains. Ten trials (30%) showed high risk of bias for randomization and 11 (33%) for assignment concealment. Six trials showed high risk of bias for each of outcome assessment<sup>31,34,39,41,47, 57</sup> and selective reporting (18%).<sup>31,33,39,41,47,57</sup> Only 2 trials (6%) had high loss to follow-up and data incompleteness.<sup>41,57</sup> Overall, two-thirds of the included trials showed low risk of bias across the 5 evaluated elements.

### Emergency cesarean deliveries in labour

Figure 2 illustrates the network of trials reporting on all emergency cesarean deliveries in labour (28 trials, including 103 676 patients). Overall, IA reduced the risk of cesarean deliveries in labour compared with other methods (IA v. CTG: RR 0.83, 95% CI 0.72–0.97; IA v. CTG-FBS: RR 0.71, 95% CI 0.63–0.80; IA v. CTG-lactate: RR 0.77, 95% CI 0.64–0.92; IA v. FPO-CTG: RR 0.75, 95% CI 0.65–0.87; IA v. FPO-CTG-FBS: RR 0.81, 95% CI 0.67–0.99; cCTG-FBS v. IA: RR 1.21, 95% CI 1.04–1.42) except when compared with STAN (STAN-CTG-FBS v. IA: RR 1.17, 95% CI 0.98–1.40) (Figure 3A). Intermittent auscultation was also most likely to reduce emergency cesarean deliveries (SUCRA 98.6), followed by STAN-CTG-FBS (SUCRA 72.3); CTG-FBS had the lowest likelihood of reducing the risk of emergency cesarean delivery (SUCRA 7.6) (Table 2, Figure 4). Using only CTG showed a similar effect on all emergency cesarean deliveries in labour compared with when it was combined with FBS (RR 1.17, 95% CI 0.99–1.40), STAN and FBS (RR 0.97, 95% CI 0.89–1.07) or with FPO (RR 1.02, 95% CI 0.91–1.16) (Appendix 1, Supplementary Figure 2). We detected




**Figure 1:** Flow chart of the study selection and inclusion process for network meta-analysis on intrapartum fetal surveillance.

**Table 1: Characteristics of included randomized trials on intrapartum fetal surveillance**

Study	Country	Settings	Sample size	Intervention	Comparison	Gestation age, wk
Amer-Wahlin et al., 2001 <sup>25</sup>	Sweden	3 labour wards	4966	STAN-CTG-FBS	CTG-FBS	> 36
Belfort et al., 2015 <sup>26</sup>	US	16 university maternity units	11 108	STAN-CTG	CTG	> 36
Bloom et al., 2006 <sup>27</sup>	US	14 university maternity units	5341	CTG-FPO	CTG	≥ 36
Brocklehurst et al., 2017 <sup>28</sup>	UK	24 maternity units	47 062	cCTG-FBS	CTG-FBS	≥ 35
Caliskan et al., 2009 <sup>29</sup>	Turkey	Tertiary referral centre	230	CTG-FPO	CTG	≥ 34
East et al., 2006 <sup>30</sup>	Australia	4 maternity hospitals	601	FPO-CTG-FBS	CTG-FBS	≥ 26
East et al., 2016 <sup>31</sup>	Australia	Tertiary referral centre	123	CTG-lactate	CTG	Full term
Garite et al., 2000 <sup>32</sup>	US	9 maternity hospitals	1010	FPO-CTG-FBS	CTG-FBS	≥ 36
Haverkamp et al., 1976 <sup>33</sup>	US	NR	483	CTG	IA	≥ 35
Haverkamp et al., 1979 <sup>34</sup>	US	General hospital	690	CTG	CTG-FBS	> 34
Haverkamp et al., 1979 <sup>34</sup>	US	General hospital	690	CTG	IA	> 34
Herbst et al., 1994 <sup>35</sup>	Sweden	Tertiary referral centre	4044	IA	CTG-FBS	> 33
Ignatov et al., 2016 <sup>36</sup>	Bulgaria	Tertiary referral centre	720	cCTG	CTG-FBS	≥ 37
Kelso et al., 1978 <sup>37</sup>	UK	Tertiary referral centre	504	CTG	IA	NR
Klauser et al., 2005 <sup>38</sup>	US	Hospital for women & infants	360	CTG-FPO	CTG	≥ 28
Kuhnert et al., 2004 <sup>39</sup>	Germany	Women's hospitals. (The German Multicenter Study Group)	146	CTG-FBS-FPO	CTG-FBS	≥ 36
Macdonald et al., 1985 <sup>40</sup>	UK	Maternity hospital	12 964	CTG-FBS	IA	≥ 28
Madaan et al., 2006 <sup>41</sup>	India	University hospital	100	CTG	IA	≥ 37
Mdoe et al., 2018 <sup>42</sup>	Tanzania	Referral hospital	2652	CTG	IA	NR
Neldam et al., 1986 <sup>43</sup>	Denmark	Labour ward in tertiary university hospital	1061	CTG-FBS	IA	≥ 36
Nunes et al., 2017 <sup>44</sup>	UK	5 hospitals, 3 tertiary care units and 2 district general hospitals	7730	cCTG-FBS	CTG-FBS	≥ 36
Ojala et al., 2006 <sup>45</sup>	Finland	Labour ward in tertiary university hospital	1483	STAN-CTG-FBS	CTG-FBS	≥ 36
Puertas et al., 2018 <sup>46</sup>	Spain	University hospital	237	STAN-CTG-FBS	CTG-FBS	291–294 d gestation
Renou et al., 1976 <sup>47</sup>	Australia	Fetal intensive care unit	440	CTG-FBS	IA	NR
Strachan et al., 2000 <sup>48</sup>	UK, Hong Kong, Netherlands, Singapore	5 teaching hospitals	1038	STAN-CTG-FBS	CTG-FBS	NR
Valverde et al., 2011 <sup>49</sup>	Spain	University hospital	180	STAN-CTG-FBS	FPO-CTG-FBS	Full term
van Wijngaarden et al., 1996 <sup>50</sup>	UK, Hong Kong	3 teaching hospitals	214	STAN-CTG-FBS	CTG-FBS	> 27
Vayssiere et al., 2007 <sup>51</sup>	France	2 maternity wards	799	STAN-CTG-FBS	CTG-FBS	≥ 36
Vintzileos et al., 1993 <sup>52</sup>	Greece	2 university hospitals	1428	CTG	IA	≥ 26
Westerhuis et al., 2010 <sup>53</sup>	Netherlands	3 academic and 6 nonacademic teaching hospitals	5681	STAN-CTG-FBS	CTG-FBS	> 36
Westgate et al. 1993 <sup>54</sup>	UK	Distric general hospital	2434	STAN-CTG-FBS	CTG-FBS	> 34
Westgren et al. 1998 <sup>55</sup>	Sweden	University hospital	341	CTG-lactate	CTG-FBS	NR
Wiberg-Itzel et al. 2008 <sup>56</sup>	Sweden	10 labour ward departments	2992	CTG-lactate	CTG-FBS	≥ 34
Wood et al. 1981 <sup>57</sup>	Australia	Maternity hospital and medical centre	989	CTG-FBS	IA	NR

Note: cCTG = computer-aided cardiotocography, cCTG-FBS = computer-aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG-FBS = cardiotocography with fetal scalp blood pH sampling, CTG-lactate = cardiotocography with fetal scalp blood lactate, FPO-CTG = cardiotocography with fetal pulse oximetry, FPO-CTG-FBS = cardiotocography with fetal pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, NR = not reported, STAN-CTG = cardiotocography with fetal heart electrocardiogram, STAN-CTG-FBS = cardiotocography with fetal heart electrocardiogram and fetal scalp blood pH sampling.



**Figure 2:** Network comparing the effectiveness of types of intrapartum fetal surveillance to reduce all emergency cesarean sections in labour. The dot size represents the number of participants in each comparison arm and the thickness of the lines represent the number of randomized trials directly comparing the pair of methods. Note: cCTG-FBS = computer-aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG-FBS = cardiotocography with fetal scalp blood pH sampling, CTG-lactate = cardiotocography with fetal scalp blood lactate, FPO-CTG = cardiotocography with fetal pulse oximetry, FPO-CTG-FBS = cardiotocography with fetal pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, STAN-CTG-FBS = cardiotocography with fetal heart electrocardiogram and fetal scalp blood pH sampling.

significant inconsistency in this network ( $p = 0.01$ ) that derived from evidence in the loop formed by CTG-FBS, FPO-CTG-FBS and STAN-CTG-FBS (Appendix 1, Supplementary Table 5).

Twenty-three trials reported on cesarean deliveries for suspected fetal distress ( $n = 100\,500$ ) (Appendix 1, Supplementary Table 3). Intermittent auscultation showed a similar effect in reducing cesarean deliveries compared with CTG (RR 0.57, 95% CI 0.38–0.86), CTG-FBS (RR 0.34, 95% CI 0.22–0.50), FPO-CTG (RR 0.42, 95% CI 0.25–0.70) and cCTG-FBS (RR 1.80, 95% CI 1.06–3.07) (Figure 3B). Combining FPO or STAN with CTG-FBS seemed to reduce the risk of cesarean deliveries for suspected fetal distress compared with using CTG-FBS alone (FPO-CTG-FBS v. CTG-FBS: RR 0.40, 95% CI 0.21–0.77; STAN-CTG-FBS v. CTG-FBS: RR 0.47, 95% CI 0.26–0.84), though there was no significant difference between the 2 combinations when compared to one another (STAN-CTG-FBS v. FPO-CTG-FBS: RR 1.16, 95% CI 0.77–1.74) (Appendix 1, Supplementary Figure 3). There was significant inconsistency in this network ( $p = 0.004$ ) that involved evidence loops for CTG-FBS, FPO-CTG-FBS and STAN-CTG-FBS (Appendix 1, Supplementary Table 5).

We further investigated the inconsistencies in the 12 trials that contributed to the evidence loop comparing CTG-FBS, FPO-CTG-FBS and STAN-CTG-FBS. Three trials compared FPO-CTG-FBS to CTG-FBS, 8 trials compared STAN-CTG-FBS to CTG-FBS and 1 trial compared STAN-CTG-FBS to FPO-CTG-FBS. All

12 trials were conducted in tertiary maternity units in high-income countries with similar study population characteristics. Two trials included patients with preterm pregnancies (CTG-FBS-FPO v. CTG-FBS<sup>30</sup> and CTG-FBS-STAN v. CTG-FBS<sup>50</sup>); the others included patients at more than 36 weeks' gestation. Only 1 trial (CTG-FBS-FPO v. CTG-FBS<sup>39</sup>) showed an overall high risk of bias, with all remaining trials showing low to medium risk of bias. All trials followed established guidelines to interpret the findings of STAN and FPO in their action algorithms (Appendix 1, Supplementary Table 4).

We conducted a metaregression to investigate the potential effect of pregnancy status (high v. low risk) and gestational age (term v. preterm) on the risk for emergency cesarean deliveries and for cesarean deliveries for suspected fetal distress. Results suggested that pregnancy status had a significant effect among trials comparing FPO-CTG-FBS with CTG-FBS (Appendix 1, Supplementary Table 6). We conducted a sensitivity analysis, excluding trials evaluating FPO-CTG-FBS, which resolved the inconsistency in both networks without any major change in the effect sizes among remaining comparison arms (Appendix 1, Supplementary Figure 4).


### Secondary outcomes

Using IA reduced the risk of all instrumental deliveries compared with using CTG alone (IA v. CTG: RR 0.82, 95% CI 0.73–0.93), but it did not show a significant difference compared with other fetal surveillance methods (Appendix 1, Supplementary Figure 5). In contrast, IA significantly reduced the risk of instrumental deliveries for suspected fetal distress compared with all other fetal surveillance methods (IA v. CTG: RR 0.41, 95% CI 0.30–0.57; IA v. CTG-FBS: RR 0.42, 95% CI 0.25–0.69; IA v. FPO-CTG-FBS: RR 0.50, 95% CI 0.32–0.79; STAN-CTG-FBS v. IA: RR 2.14, 95% CI 1.49–3.08; cCTG-FBS v. IA: RR 2.52, 95% CI 1.77–3.60) (Appendix 1, Supplementary Figure 6).

All types of fetal surveillance had a similar effect on the evaluated neonatal outcomes (neonatal acidemia, admission to neonatal unit, Apgar < 7 at 5th minute and perinatal death) (Appendix 1, Supplementary Figure 7–10). Table 2 shows the ranking of all evaluated types of surveillance according to their likelihood of reducing adverse neonatal outcomes. Combining FPO or STAN with CTG-FBS seemed to improve the likelihood of reducing adverse neonatal outcomes, but this did not result in a significant difference in our network meta-analysis. We did not detect significant inconsistency in the evidence networks for any of the secondary outcomes.

### Sensitivity analysis

Our network meta-analysis that included the 2 trials evaluating the use of STAN-CTG and cCTG alone on emergency cesarean deliveries showed that the use of STAN-CTG had a similar effect on the risk of all emergency cesarean deliveries compared with other surveillance methods except STAN-CTG-FBS (RR 0.79, 95% CI 0.64–0.98) and IA (RR 1.47, 95% CI 1.28–1.70) (Appendix 1, Supplementary Figures 11 and 12). A similar effect was seen for cesarean deliveries for suspected fetal distress (Appendix 1, Supplementary Figure 12).



**Figure 3:** Network meta-analysis comparing the effectiveness of intermittent auscultation (IA) to reduce (A) all emergency cesarean deliveries in labour and (B) emergency cesarean deliveries for suspected fetal distress. The forest plots depict the effectiveness of IA compared with other types of fetal surveillance using both mixed evidence network meta-analysis (M) and direct evidence pairwise meta-analysis (D). Note: cCTG-FBS = computer-aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG-FBS = cardiotocography with fetal scalp blood pH sampling, CTG-lactate = cardiotocography with fetal scalp blood lactate, FPO-CTG = cardiotocography with fetal pulse oximetry, FPO-CTG-FBS = cardiotocography with fetal pulse oximetry and fetal blood pH sampling, LCL = lower confidence limit, RR = risk ratio, STAN-CTG-FBS = cardiotocography with fetal heart electrocardiogram and fetal scalp blood pH sampling, UCL = upper confidence limit.

Network meta-analysis on the use of cCTG alone suggested a consistent reduction in the relative risk for all emergency cesarean deliveries by around 50% compared with all other surveillance methods (Appendix 1, Supplementary Figure 11). No data were available on the effect of cCTG on cesarean deliveries for suspected fetal distress. Given the potential high risk of bias and inconsistency between the indirect and the direct evidence sought from this small trial, we interpret these findings with caution.

## Interpretation

Despite the large investment in developing intrapartum fetal surveillance technology over the last 5 decades, our network meta-analysis suggests that none of the newer surveillance methods seem to significantly reduce emergency cesarean deliveries in labour or neonatal morbidity compared with using simple IA of the fetal heart. Combining newer methods such as STAN and FPO with CTG may improve its performance, thus reducing

**Table 2: Summary of the calculated surface under the cumulative ranking curve (SUCRA) and mean rank for types of intrapartum fetal surveillance across maternal and neonatal outcomes\***

Outcomes	IA		CTG		CTG-FBS		CTG-lactate		STAN-CTG-FBS		FPO-CTG		FPO-CTG-FBS		cCTG-FBS	
	SUCRA %	Mean rank	SUCRA %	Mean rank	SUCRA %	Mean rank	SUCRA %	Mean rank	SUCRA %	Mean rank	SUCRA %	Mean rank	SUCRA %	Mean rank	SUCRA %	Mean rank
<b>Maternal outcomes</b>																
Any EmCD	98.6	1.1	63.1	3.6	7.6	7.5	25.4	6.2	72.3	2.9	30.8	5.8	49.0	4.6	53.2	4.3
EmCD for suspected fetal distress	93.2	1.4	40.5	4.6	3.2	6.8	N/A	N/A	40.0	4.6	23.0	5.6	81.8	2.1	N/A	N/A
Any Instrumental delivery	87.6	1.9	25.7	6.2	64.6	3.5	45.6	4.8	22.3	6.4	63.0	3.6	36.5	5.4	N/A	N/A
Instrumental delivery for suspected fetal distress	100.0	1.0	26.3	4.7	33.5	4.3	N/A	N/A	57.7	3.1	N/A	N/A	64.7	2.8	17.8	5.1
<b>Neonatal outcomes</b>																
Acidemia	51.8	4.4	38.9	5.3	15.5	6.9	63.7	3.5	71.2	3.0	35.5	5.5	76.2	2.7	47.2	4.7
Admission to NICU	42.1	5.1	38.3	5.3	49.3	4.6	37.0	5.4	75.7	2.7	78.3	2.5	10.5	7.3	68.9	3.2
Apgar < 7 at 5th minute	75.9	2.7	26.3	6.2	64.4	3.5	13.9	7.0	39.2	5.3	52.4	4.3	79.4	2.4	48.4	4.6
Perinatal death	44.8	4.3	46.8	4.2	69.1	2.9	N/A	N/A	36.0	4.8	80.0	2.2	32.1	5.1	41.2	4.5

Note: cCTG-FBS = computer-aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG-FBS = cardiotocography with fetal scalp blood pH sampling, CTG-lactate = cardiotocography with fetal scalp blood lactate, EmCD = emergency cesarean delivery, FPO-CTG = cardiotocography with fetal pulse oximetry, FPO-CTG-FBS = cardiotocography with fetal pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, N/A = no available evidence, NICU = neonatal intensive care unit, STAN-CTG-FBS = cardiotocography with fetal heart electrocardiogram and fetal scalp blood pH sampling.

\*The calculated SUCRA for all adverse outcomes expresses the lowest likelihood of developing adverse maternal and neonatal outcomes.


unnecessary cesarean deliveries. However, none of these combinations were shown to significantly outperform IA in reducing adverse maternal and neonatal outcomes. Although there were variations in the quality and reporting across trials, leading to inconsistency in the evidence networks on cesarean delivery outcomes, the effect estimates favouring IA across all evaluated types of surveillance were consistent in our sensitivity analyses, thereby increasing the generalizability of our findings. Trials evaluating the use of FPO contributed to statistical inconsistency when evaluating the incidence of emergency cesarean deliveries. As such, the direct and indirect evidence on the effect of FPO should be interpreted with caution, pending larger trials to better evaluate its effectiveness.

Our review provides a uniquely comprehensive evidence synthesis on all current types of fetal surveillance for intrapartum care. We leveraged both direct and indirect evidence from randomized trials using the network meta-analysis methodology to compare and rank types of surveillance not previously evaluated in pairwise meta-analyses (e.g., IA v. STAN). Our systematic review adopted a pragmatic approach to report on all relevant endpoints, as reported by the authors, to synthesize the most comprehensive evidence on the topic that could directly apply to clinical practice. We assessed the risk of bias using a standard

tool and took into account any quality improvement measures to improve the validity of each trial, given the complexity of the evaluated interventions and the chance of methodological heterogeneity. To reduce the risk of inconsistency in our network, we eliminated methods of surveillance evaluated by a single trial (cCTG and CTG-STAN) from the primary analysis and performed supplementary analyses to assess the true effect of these methods. We examined for inconsistency using the node-split approach and conducted a meta-regression, which found that the detected inconsistency could be explained by whether pregnancy status was high or low risk.

All currently available methods of intrapartum fetal surveillance assume that detecting subtle changes and variability in the fetal heart rate could identify fetuses at risk of intrapartum asphyxia, prompting further interventions.<sup>58</sup> Simultaneously, fetal surveillance aims to identify those fetuses coping well with labour, regardless of the subtle changes in the fetal heart rate, to avoid unnecessary interventions, reassure mothers and their health care providers.<sup>58</sup> Introducing IA into practice helped to improve the detection of acutely compromised fetuses after serious events such as placental abruption, thus reducing associated adverse outcomes.<sup>59</sup> However, its accuracy to detect subacute hypoxia and chronic intrapartum insult remains debatable.<sup>3</sup> Our





**Figure 4:** The ranking probability of types of intrapartum fetal surveillance to reduce all emergency cesarean deliveries when used in labour. The graph depicts the probability of each type to be ranked the highest in reducing the incidence of all emergency cesarean deliveries in labour. IA was consistently ranked first, followed by STAN-CTG-FBS and CTG-FBS. Note: cCTG = computer-aided cardiotocography, cCTG-FBS = computer-aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG-FBS = cardiotocography with fetal scalp blood pH sampling, CTG-lactate = cardiotocography with fetal scalp blood lactate, FPO-CTG = cardiotocography with fetal pulse oximetry, FPO-CTG-FBS = cardiotocography with fetal pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, STAN-CTG = cardiotocography with fetal heart electrocardiogram, STAN-CTG-FBS = cardiotocography with fetal heart electrocardiogram and fetal scalp blood pH sampling.

analysis suggests that all additional methods introduced to improve the accuracy of electronic fetal heart monitoring (CTG, FBS, FPO, STAN and cCTG) have failed to reduce the risk of adverse neonatal or maternal outcomes beyond what IA achieved 50 years ago, and this may have contributed to the increased incidence of unnecessary emergency cesarean deliveries. As such, the benefit of these newer surveillance methods is questionable, especially in view of the consistent rise in the rate of cesarean deliveries worldwide. The increasing incidence of cesarean deliveries is particularly notable in high-income countries where advanced fetal surveillance methods are readily available. The suboptimal performance of newer fetal surveillance methods could be mediated by a higher false-positive detection rate or human errors in interpreting their outputs, driven by operator incompetence or increased interface complexity. Clearly, the rising rate of cesarean deliveries is multifactorial<sup>60</sup> and cannot be linked solely to poorly performing intrapartum fetal surveillance methods. More specifically, our findings suggest that these technologies failed to meet their objective of reducing unnecessary interventions in labour.

Most included trials failed to report on key long-term neonatal outcomes, such as cerebral palsy, neonatal seizures and hypoxic-ischemic encephalopathy. Instead, most reported on short-term, readily recorded outcomes, such as neonatal

acidemia and Apgar scores, all of which have a modest correlation with long-term child development.<sup>61</sup> Similarly, there was poor reporting on important long-term maternal outcomes following cesarean deliveries and instrumental deliveries, such as subsequent placenta accreta and anal sphincter injuries.<sup>62</sup> Those long-term outcomes should be considered in future trials and their follow-ups, especially given the contrast between randomized and observational evidence on the effect of adopting newer fetal surveillance methods in practice.<sup>4</sup>

Given the inconsistency in evidence on the use of FPO and STAN compared with CTG-FBS, large, randomized trials are needed to determine their effectiveness in both high- and low-risk pregnancies when implemented in routine practice, especially given the potential high costs (e.g., hardware, software and staff training). Novel study designs such as multiarm, multistage comparison and cluster randomization trials may be better suited to evaluate the efficacy and effectiveness of fetal surveillance in everyday clinical settings. Specifically, these trials should aim to evaluate the preferential use of IA and CTG in low- v. high-risk pregnant people as well as the effectiveness of different fetal surveillance algorithms across different health care settings (e.g high- v. low-income countries).

Developing and evaluating new fetal surveillance methods is a complex, expensive and time-consuming endeavour because of

the increased safety requirements in clinical research. Given the modest improvement in neonatal and maternal outcomes over the last 50 years, boosting collaboration among researchers, funders, industry, policymakers and lay consumers is required to tackle this important health issue.<sup>63</sup> The rapid improvement in communication technology could facilitate this objective and foster transcountry collaborations to aid joint research efforts and data sharing. Our meta-analysis makes the case for serious investment in the development and evaluation of novel intrapartum surveillance technologies to make birth a safer process for patients and their offspring.

### Limitations

Several of the trials included in our meta-analysis were relatively old. Their quality differs compared with newer trials, especially for the elements of randomization, assignment concealment and outcome assessment. This was particularly relevant to trials comparing IA and CTG.<sup>33–35,37,40–43,47,52,57</sup> Limited reporting on attrition, and the use of intention-to-treat analysis were provided in some trials, particularly those before 2000. We included these trials to minimize research waste, but also to highlight the elements of suboptimal design. Furthermore, we assessed their risk of bias to offer a comprehensive overview of changes in fetal surveillance over time. Several older trials included participants with different pregnancy status (high v. low risk) using different selection criteria. This could have an impact on effect sizes, though we did not detect a statistically significant effect in our meta-regression. A number of trials adopted different criteria for interpreting CTGs and fetal well-being, which might bias the findings. However, none of the evaluated criteria seemed to offer better accuracy for detecting fetal compromise in labour.<sup>64</sup> The definition of neonatal acidemia has evolved over the years, which resulted in variation across trials. We were unable to accommodate several potential effect modifiers, such as progress in labour, induction of labour, suspected fetal growth restriction, use of oxytocin augmentation, operator experience and deviation from the trial's protocol. Although some of these elements could be adjusted for in an individual patient data meta-analysis, several factors are difficult to measure in practice, such as severity of sepsis in labour and degree of fetal growth restriction. Lastly, most of the included trials were underpowered to detect rare adverse neonatal outcomes and were potentially affected by the Hawthorne effect, limiting their generalizability. Our comprehensive analysis therefore offers a pragmatic approach that synthesizes the best quality evidence available to-date and guides future research efforts to address these limitations.

### Conclusion

Compared with other types of fetal surveillance, intermittent auscultation seems to reduce emergency cesarean deliveries in labour without increasing adverse neonatal and maternal outcomes. New fetal surveillance methods did not improve neonatal outcomes or reduce unnecessary maternal interventions. Further evidence is needed to evaluate the effects of fetal pulse oximetry and fetal heart electrocardiography in labour.

### References

- Jibodu OA, Arulkumaran S. Intrapartum fetal surveillance. *Curr Opin Obstet Gynecol* 2000;12:123-7.
- Intrapartum care for healthy women and babies. London (UK): The National Institute for Health and Care Excellence; 2014; Available: <https://www.nice.org.uk/guidance/cg190> (accessed 2021 Jan. 1).
- Steer PJ. Has electronic fetal heart rate monitoring made a difference? *Semin Fetal Neonat Med* 2008;13:2-7.
- Olofsson P, Ayres de Campos D, Kessler J, et al. A critical appraisal of the evidence for using cardiotocography plus ECG ST interval analysis for fetal surveillance in labor. Part II: the meta analyses. *Acta Obstet Gynecol Scand* 2014;93:571-86.
- Carbonne B, Pons K, Maisonneuve E. Foetal scalp blood sampling during labour for pH and lactate measurements. *Best Pract Res Clin Obstet Gynaecol* 2016;30:62-7.
- INFANT Collaborative Group. Computerised interpretation of fetal heart rate during labour (INFANT): a randomised controlled trial. *Lancet* 2017;389:1719-29.
- Molina G, Weiser TG, Lipsitz SR, et al. Relationship between cesarean delivery rate and maternal and neonatal mortality. *JAMA* 2015;314:2263-70.
- Blencowe H, Cousens S, Jassir FB, et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. *Lancet Glob Health* 2016;4:e98-108.
- Thacker SB, Stroup D, Chang M. Continuous electronic heart rate monitoring for fetal assessment during labor. *Cochrane Database Syst Rev* 2001;(2):CD000063.
- Alfirevic Z, Gyte GML, Cuthbert A, et al. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. *Cochrane Database Syst Rev* 2017;(2):CD006066.
- East CE, Begg L, Colditz PB, et al. Fetal pulse oximetry for fetal assessment in labour. *Cochrane Database Syst Rev* 2014;(10):CD004075.
- Martis R, Emilia O, Nurdiani DS, et al. Intermittent auscultation (IA) of fetal heart rate in labour for fetal well being. *Cochrane Database Syst Rev* 2017;(2): CD008680.
- Saccone G, Schuit E, Am-Wählin I, et al. Electrocardiogram ST analysis during labor: a systematic review and meta-analysis of randomized controlled trials. *Obstet Gynecol* 2016;127:127-35.
- Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777-84.
- Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta analysis: model estimation using multivariate meta regression. *Res Synth Methods* 2012;3:111-25.
- White IR. Network meta-analysis. *Stata J* 2015;15:951-85.
- Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163-71.
- Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8:e76654.
- Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta analysis: concepts and models for multiarm studies. *Res Synth Methods* 2012;3:98-110.
- Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta analysis. *Stat Med* 2010;29:932-44.
- Veroniki AA, Vasiliadis HS, Higgins JPT, et al. Evaluation of inconsistency in networks of interventions. *Int J Epidemiol* 2013;42:332-45.
- Dias S, Ades AE, Welton NJ, et al. *Network meta-analysis for decision-making*. Hoboken (NJ): John Wiley & Sons; 2018.
- White IR. Multivariate random-effects meta-regression: updates to mvmeta. *Stata J* 2011;11:255-70.
- Amer-Wählin I, Hellsten C, Norén H, et al. Cardiotocography only versus cardiotocography plus ST analysis of fetal electrocardiogram for intrapartum fetal monitoring: a Swedish randomised controlled trial. *Lancet* 2001;358:534-8.
- Belfort MA, Saade GR, Thom E, et al. A randomized trial of intrapartum fetal ECG ST-segment analysis. *N Engl J Med* 2015;373:632-41.
- Bloom SL, Spong CY, Thom E, et al. Fetal pulse oximetry and cesarean delivery. *N Engl J Med* 2006;355:2195-202.
- INFANT Collaborative Group. Computerised interpretation of fetal heart rate during labour (INFANT): a randomised controlled trial. *Lancet* 2017;389:1719-29.
- Caliskan E, Cakiroglu Y, Corakci A, et al. Reduction in caesarean delivery with fetal heart rate monitoring and intermittent pulse oximetry after induction of labour with misoprostol. *J Matern Fetal Neonatal Med* 2009;22:445-51.
- East CE, Brennecke SP, King JF, et al., FOREMOST Study Group. The effect of intrapartum fetal pulse oximetry, in the presence of a nonreassuring fetal heart rate pattern, on operative delivery rates: a multicenter, randomized, controlled trial (the FOREMOST trial). *Am J Obstet Gynecol* 2006;194:606-e1-16.

31. East C, Davey MA, Kamlin O, et al. Randomised trial of fetal scalp blood sampling for lactate measurement: The Flamingo trial. *BJOG* 2016;123.
32. Garite TJ, Dildy GA, McNamara H, et al. A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns. *Am J Obstet Gynecol* 2000;183:1049-58.
33. Haverkamp AD, Thompson HE, McFee JG, et al. The evaluation of continuous fetal heart rate monitoring in high-risk pregnancy. *Am J Obstet Gynecol* 1976;125:310-20.
34. Haverkamp AD, Orleans M, Langendoerfer S, et al. A controlled trial of the differential effects of intrapartum fetal monitoring. *Am J Obstet Gynecol* 1979;134:399-412.
35. Herbst A, Ingemarsson I. Intermittent versus continuous electronic monitoring in labour: a randomised study. *Br J Obstet Gynaecol* 1994;101:663-8.
36. Ignatov PN, Lutomski JE. Quantitative cardiotocography to improve fetal assessment during labor: a preliminary randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol* 2016;205:91-7.
37. Kelso IM, Parsons RJ, Lawrence GF, et al. An assessment of continuous fetal heart rate monitoring in labor: a randomized trial. *Am J Obstet Gynecol* 1978;131:526-32.
38. Klausner CK, Christensen EE, Chauhan SP, et al. Use of fetal pulse oximetry among high-risk women in labor: a randomized clinical trial. *Am J Obstet Gynecol* 2005;192:1810-7.
39. Kühnert M, Schmidt S. Intrapartum management of nonreassuring fetal heart rate patterns: a randomized controlled trial of fetal pulse oximetry. *Am J Obstet Gynecol* 2004;192:1989-95.
40. MacDonald D, Grant A, Sheridan-Pereira M, et al. The Dublin randomized controlled trial of intrapartum fetal heart rate monitoring. *Am J Obstet Gynecol* 1985;152:524-39.
41. Madaan M, Trivedi SS. Intrapartum electronic fetal monitoring vs. intermittent auscultation in postcesarean pregnancies. *Int J Gynaecol Obstet* 2006;94:123-5.
42. Mdoe PF, Ersdal HL, Mduma E, et al. Randomized controlled trial of continuous Doppler versus intermittent fetoscope fetal heart rate monitoring in a low resource setting. *Int J Gynaecol Obstet* 2018;143:344-50.
43. Neldam S, Osler M, Hansen PK, et al. Intrapartum fetal heart rate monitoring in a combined low-and high-risk population: a controlled clinical trial. *Eur J Obstet Gynecol Reprod Biol* 1986;23:1-11.
44. Nunes I, Ayres-de-Campos D, Ugwumadu A, et al. Central fetal monitoring with and without computer analysis. *Obstet Gynecol* 2017;129:83-90.
45. Ojala K, Väärasmäki M, Mäkilä K, et al. A comparison of intrapartum automated fetal electrocardiography and conventional cardiotocography—a randomized controlled study. *BJOG* 2006;113:419-23.
46. Puertas A, Góngora J, Valverde M, et al. Cardiotocography alone vs. cardiotocography with ST segment analysis for intrapartum fetal monitoring in women with late-term pregnancy. A randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol* 2019;234:213-7.
47. Renou P, Chang A, Anderson I, et al. Controlled trial of fetal intensive care. *Am J Obstet Gynecol* 1976;126:470-6.
48. Strachan BK, van Wijngaarden WJ, Sahota D, et al., FECG Study Group. Cardiotocography only versus cardiotocography plus PR-interval analysis in intrapartum surveillance: a randomised, multicentre trial. *Lancet* 2000;355:456-9.
49. Valverde M, Puertas AM, Lopez-Gallego MF, et al. Effectiveness of pulse oximetry versus fetal electrocardiography for the intrapartum evaluation of nonreassuring fetal heart rate. *Eur J Obstet Gynecol Reprod Biol* 2011;159:333-7.
50. van Wijngaarden WJ, Sahota DS, James DK, et al. Improved intrapartum surveillance with PR interval analysis of the fetal electrocardiogram: a randomized trial showing a reduction in fetal blood sampling. *Am J Obstet Gynecol* 1996;174:1295-9.
51. Vayssière C, David E, Meyer N, et al. A French randomized controlled trial of ST-segment analysis in a population with abnormal cardiotocograms during labor. *Am J Obstet Gynecol* 2007;197:299-e1.
52. Vintzileos AM, Antsaklis A, Varvarigos I, et al. A randomized trial of intrapartum electronic fetal heart rate monitoring versus intermittent auscultation. *Obstet Gynecol* 1993;81:899-907.
53. Westerhuis ME, Moons KG, van Beek E, et al. A randomised clinical trial on cardiotocography plus fetal blood sampling versus cardiotocography plus ST-analysis of the fetal electrocardiogram (STAN®) for intrapartum monitoring. *BMC Pregnancy Childbirth* 2007;7:1-8.
54. Westgate J, Harris M, Curnow JS, et al. Randomised trial of cardiotocography alone or with ST waveform analysis for intrapartum monitoring. *Lancet* 1992;340:194-8.
55. Westgren M, Kruger K, Ek S, et al. Lactate compared with pH analysis at fetal scalp blood sampling: a prospective randomised study. *BJOG* 1998;105:29-33.
56. Wiberg-Itzel E, Lipponer C, Norman M, et al. Determination of pH or lactate in fetal scalp blood in management of intrapartum fetal distress: randomised controlled multicentre trial. *BMJ* 2008;336:1284-7.
57. Wood C, Renou P, Oats J, et al. A controlled trial of fetal heart rate monitoring in a low-risk obstetric population. *Am J Obstet Gynecol* 1981;141:527-34.
58. Devoe LD. Future perspectives in intrapartum fetal surveillance. *Best Pract Res Clin Obstet Gynaecol* 2016;30:98-106.
59. Goddard R. Electronic fetal monitoring: is not necessary for low risk labours. *BMJ* 2001;322:1436-7.
60. Betrán AP, Torloni MR, Zhang J-J, et al. WHO statement on caesarean section rates. *BJOG* 2016;123:667-70.
61. Sabol BA, Caughey AB. Acidemia in neonates with a 5-minute Apgar score of 7 or greater — What are the outcomes? *Am J Obstet Gynecol* 2016;215:486.e1-6.
62. Grivell RM, Dodd JM. Short- and long-term outcomes after cesarean section. *Expert Rev Obstet Gynecol* 2011;6:205-15.
63. Adam J. The future of fetal monitoring. *Rev Obstet Gynecol* 2012;5:e132-6.
64. Garabedian C, Butruille L, Drumez E, et al. Inter-observer reliability of 4 fetal heart rate classifications. *J Gynecol Obstet Hum Reprod* 2017;46:131-5.

**Competing interests:** None declared.

This article has been peer reviewed.

**Affiliations:** Warwick Medical School (Al Wattar, Honess, Bunnewell, Quenby), University of Warwick, Coventry, UK; Reproductive Medicine Unit (Al Wattar), University College London Hospitals, London, UK; Population Health Sciences (Welton), Bristol Medical School, University of Bristol, Bristol, UK; University Hospital of Coventry and Warwickshire (Quenby), Coventry, UK; Department of Preventive Medicine and Public Health (Khan), University of Granada, Granada, Spain; Clinical Biostatistics Unit, Ramon y Cajal Hospital (IRYCIS) and CIBER Epidemiology and Public Health (Khan, Zamora), Madrid, Spain; CIBER of Epidemiology and Public Health (CIBERESP) (Zamora), Madrid, Spain; WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research (Thangaratnam), University of Birmingham; Birmingham Women's and Children's NHS Foundation Trust (Thangaratnam), Birmingham, UK

**Contributors:** Bassel Al Wattar conceived and designed the study. Bassel Al Wattar, Emma Honess and Sarah Bunnewell acquired the data. All authors contributed to the analysis and interpretation of data. Bassel Al Wattar drafted the initial manuscript, which all authors critically revised for important intellectual content. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

**Content licence:** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

**Funding:** Bassel Al Wattar holds a personal Academic Clinical Lectureship from the UK National Health Institute of Research. Khalid

Khan is a Distinguished Investigator funded by the Beatriz Galindo (senior modality) Program Grant given to the University of Granada by the Ministry of Science, Innovation, and Universities of the Spanish Government.

**Copyright:** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

**Data sharing:** All data included in this study is available to other researchers for use in scientific research. Requests should be made to the corresponding authors stating the purpose and type of data required.

**Accepted:** Jan. 18, 2021

**Correspondence to:** Bassel Al Wattar, dr. [basselwa@gmail.com](mailto:basselwa@gmail.com)